

October 31, 2024



Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024

SAN JOSE, Calif., Oct. 31, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its presentation at the Sidoti Micro-Cap Virtual Conference, taking place November 13-14, 2024. Anixa Chairman and CEO Dr. Amit Kumar will present an overview of the Company and its clinical programs.

Conference details:

Presentation: Thursday, November 14, 2024, at 1:00pm ET

Presentation link: [Click here](#) to register; available via Zoom

Conference registration: Available on the [conference website](#)

1x1 meetings: Open to all investors upon conference registration

Dr. Kumar stated, "We are pleased to present at this conference, shortly after release of the most up-to-date data from our breast cancer clinical trial, which will occur on November 8, 2024. We will also provide updates to our CAR-T trial for recurrent and resistant ovarian cancer patients. Both trials are producing very positive results, exceeding all of our expectations, and we look forward to providing an update."

About Anixa Biosciences, Inc.

Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that

have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on [Twitter](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

Forward-Looking Statements

Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:

Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808

View original content: <https://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-the-sidoti-micro-cap-virtual-conference-on-november-13--14-2024-302292348.html>

SOURCE Anixa Biosciences, Inc.